Secukinumab efficacy in subjects with moderate to severe plaque psoriasis: Pooled subgroup analyses by patient age of 4 phase 3 clinical studies - 16/03/14
Doi : 10.1016/j.jaad.2014.01.771
Le texte complet de cet article est disponible en PDF.
Richard Warren, Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; Achim Guettner, Novartis Pharma AG, Basel, Switzerland; Akimichi Morita, Department of Geriatric and Environmental Dermatology, Nagoya City University, Graduate School of Medical Science, Nagoya, Japan; Paolo Gisondi, Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy; Simon Cooper, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States
Le texte complet de cet article est disponible en PDF.| Sponsored by Novartis Pharma AG, Basel, Switzerland. |
© 2014
Publié par Elsevier Masson SAS.
Vol 70 - N° 5S1
P. AB186 - mai 2014 Retour au numéro
Article précédent
- Secukinumab efficacy in subjects with moderate to severe plaque psoriasis: A pooled analysis of patient-reported symptoms (pruritus, pain, and scaling) in 2 phase 3 clinical studies (ERASURE and FIXTURE)
- Secukinumab efficacy stratified by body weight: A subanalysis from the ERASURE study
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?